Submitted by Anonymous (not verified) on 20 August 2025 - 12:57
Human medicines European public assessment report (EPAR): Rimmyrah, ranibizumab, Date of authorisation: 05/01/2024, Revision: 3, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Rimmyrah, ranibizumab, Date of authorisation: 05/01/2024, Revision: 3, Status: Authorised